GET DAILY SIGNALSSensus Healthcare (SRTS) Earnings Preview: Key Questions Ahead of the November Report
Key Takeaways
- Sensus Healthcare is scheduled to release third-quarter 2026 results after the market closes on November 12, 2026, followed by a conference call.
- Consensus estimates call for a loss of about $0.06 per share on revenue near $6.61 million, versus a loss of $0.06 per share and revenue of $6.88 million in the same quarter last year.
- This marks the second full quarter under new dedicated CPT reimbursement codes effective January 1, 2026, which management views as an important catalyst for wider adoption of its superficial radiotherapy systems.
- Attention will center on whether the eight device sales delayed from the second quarter due to financing timing are recognized in third-quarter revenue.
- Given recent misses versus consensus, focus areas include revenue recognition, unit shipments, and gross margin trends.
Why This Earnings Report Matters
Sensus Healthcare’s third-quarter update represents an important checkpoint as the company works to broaden adoption of its SRT-100 and SRT-100 Vision devices beyond a historically concentrated customer base. The first half of 2026 was largely spent educating physicians on the new CPT codes, which management believes have improved customer economics and accelerated adoption cycles. Revenue has been lumpy during the transition, with second-quarter results of $2.29 million reflecting eight units that shifted into the third quarter because of financing delays. With management expecting a stronger second half overall, this report will help clarify whether the reimbursement changes are translating into actual revenue and whether the company is regaining momentum toward its full-year profitability target.
Consensus Estimates and Recent Results
Heading into the release, analysts are looking for a loss of roughly $0.06 per share on revenue of approximately $6.61 million. That compares with a loss of $0.06 per share and revenue of $6.88 million a year earlier, implying a modest year-over-year revenue decline with earnings per share essentially flat. The bar is relatively low compared with the company’s longer-term track record, yet recent quarters have frequently come in below expectations on both the top and bottom lines.
In the second quarter, Sensus reported revenue of $2.29 million and a net loss of $8.7 million, or $0.53 per share. Management cited financing timing for the shortfall and noted that the eight deferred units were later approved and sold at an average price near $250,000. Investors will therefore pay close attention to unit shipments, the mix of outright sales versus recurring-revenue arrangements, gross margin performance, and any updates on the second-half pipeline.
Investor Sentiment and Market Reaction
Sentiment ahead of the report is measured. The stock has come under pressure after multiple quarters of missed expectations and a sharp year-over-year revenue contraction tied to the shift away from a major customer. At the same time, investors focused on the positive side note the new reimbursement codes, an expanding pipeline, movement toward recurring revenue through the Fair Deal Agreement program and Sensus Link software, and management’s guidance for a stronger second half. The market’s response will likely depend on whether the delayed second-quarter sales appear in third-quarter results and whether gross margin, which fell to 29.2% in the first quarter, shows signs of stabilization.
Key Factors to Monitor Beyond the Quarter
Looking further ahead, several elements will influence the company’s path. Revenue conversion remains central, with management expecting the eight delayed units to be booked in the third quarter and commentary on fourth-quarter shipments indicating whether the improvement is sustainable. Updates on the reimbursement environment, including any progress on a proposed 26% increase in a hospital-based delivery code, will also matter. Growth in recurring revenue streams such as the Fair Deal Agreement program, rentals, and Sensus Link software is key to reducing lumpiness. Margin trends and operating expenses deserve watching given product-mix pressures, and the company’s roughly $15.2 million cash position with no debt at the end of the second quarter provides some runway, though cash burn will remain a focus.
Checking Sector Context With AI Tools
When reviewing names like SRTS alongside other medical-device companies, I sometimes run a quick scan with Tickeron’s AI Screener to compare technical signals and momentum across the group.
Using Tickeron’s AI Screener in Practice
In my own workflow, Tickeron’s AI Screener has become a useful starting point for quickly filtering medical-device stocks by technical patterns, fundamentals, and AI-driven signals. It helps surface relevant peers and trends without spending hours on manual screening, allowing more time to focus on the specific drivers for a name like Sensus Healthcare.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SRTS's RSI Oscillator peaks and leaves overbought zone
The 10-day RSI Indicator for SRTS moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 instances where the indicator moved out of the overbought zone. In 27 of the 31 cases the stock moved lower in the days that followed. This puts the odds of a move down at 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
SRTS moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
SRTS broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SRTS entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on SRTS as a result. In 78 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for SRTS just turned positive on November 03, 2026. Looking at past instances where SRTS's MACD turned positive, the stock continued to rise in 35 of 39 cases over the following month. The odds of a continued upward trend are 90%.
Following a +3.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRTS advanced for three days, in 226 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.304) is normal, around the industry mean (4.115). P/E Ratio (-3.106) is within average values for comparable stocks, (1.586). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.874) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 38 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. SRTS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of skin cancer treatment products
Industry MedicalNursingServices
Advertisement